Current strategies in the management of Barrett's esophagus

Current Gastroenterology Reports

Volumn 7, Issue 3, 2005, Pages 196-201

  Wang, Kenneth K ^a  

^a ST MARY S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINOLEVULINIC ACID; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; KI 67 ANTIGEN; NEODYMIUM; OMEPRAZOLE; ORNITHINE DECARBOXYLASE; PHOTOFRIN; PHOTOSENSITIZING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN P16; PROTEIN P53; PROTON PUMP INHIBITOR; YTTRIUM;

BARRETT ESOPHAGUS; CANCER RISK; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL TRIAL; DRUG PENETRATION; DYSPLASIA; ENDOSCOPIC BIOPSY; ENDOSCOPIC THERAPY; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; HUMAN; INCIDENCE; LOW LEVEL LASER THERAPY; NEODYMIUM LASER; PATIENT CARE; PHOTODYNAMIC THERAPY; REVIEW;

EID: 21444434405     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-005-0034-9     Document Type: Review

References (38)

1. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS: Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 2000, 119:333-338.
2. Montgomery E, Bronner MP, Goldblum JR, et al.: Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Human Pathol 2001, 32:368-378.
3. Krishnadath KK, Reid BJ, Wang KK: Biomarkers in Barrett esophagus. Mayo Clin Proc 2001, 76:438-446.
4. Rabinovitch PS, Longton G, Blount PL, et al.: Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001, 96:3071-3083.
5. Reid BJ, Prevo LJ, Galipeau PC, et al.: Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001, 96:2839-2848.
6. Sampliner RE: Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus [see comments]. Am J Gastroenterol 1994, 89:1844-1848.
7. Buttar NS, Wang KK, Sebo TJ, et al.: Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001, 120:1630-1639.
8. Ye W, Chow WH, Lagergren J, et al.: Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastro-esophageal reflux diseases and after antireflux surgery. Gastroenterology 2001, 121:1286-1293.
9. Buttar NS, Wang KK, Anderson MA, et al.: The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst 2002, 94:422-429.
10. Buttar NS, Wang KK, Leontovich O, et al.: Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002, 122:1101-1112.
11. Corley DA, Kerlikowske K, Verma R, Buffler P: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47-56.
12. Pacifico RJ, Wang KK, Wongkeesong LM, et al.: Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 2003, 1:252-257.
13. Egger K, Werner M, Meining A, et al.: Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques. Gut 2003, 52:18-23.
14. Satodate H, Inoue H, Yoshida T, et al.: Circumferential EMR of carcinoma arising in Barrett's esophagus: case report. Gastrointest Endosc 2003, 58:288-292.
15. Seewald S, Akaraviputh T, Seitz U, et al.: Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 2003, 57:854-859.
16. Ell C, May A, Gossner L, et al.: Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000, 118:670-677.
17. Inoue H, Endo M: Endoscopic esophageal mucosal resection using a transparent tube. Surg Endosc 1990, 4:198-201.
18. Inoue M, Shiozaki H, Tamura S, Monden M: Endoscopic mucosal resection for early esophageal cancer. Review 15 refs Japanese. Nippon Rinsho Jpn J Clin Med 1996, 54:1286-1291.
19. Inoue H, Kawano T, Tani M, et al.: Endoscopic mucosal resection using a cap: techniques for use and preventing perforation. Can J Gastroenterol 1999, 13:477-480.
20. Pacifico RJ, Wang KK: Role of mucosal ablative therapy in the treatment of the columnar-lined esophagus. Chest Surg Clin North Am 2002, 12:185-203.
21. Nijhawan PK, Wang KK: Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest Endosc 2000, 52:328-332.
22. Ahmad NA, Kochman ML, Long WB, et al.: Efficacy, safety, and clinical outcomes of endoscopic mucosal resection: a study of 101 cases. Gastrointest Endosc 2002, 55:390-396.
23. Noguchi H, Naomoto Y, Kondo H, et al.: Evaluation of endoscopic mucosal resection for superficial esophageal carcinoma. Surg Laparosc Endosc Percutan Tech 2000, 10:343-350.
24. Van Laethem JL, Jagodzinski R, Peny MO, et al.: Argon plasma coagulation in the treatment of Barrett's high-grade dysplasia and in situ adenocarcinoma. Endoscopy 2001, 33:257-261.
25. May A, Gossner L, Gunter E, et al.: Local treatment of early cancer in short Barrett's esophagus by means of argon plasma coagulation: initial experience. Endoscopy 1999, 31:497-500.
26. Weston AP, Sharma P: Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma. Am J Gastroenterol 2002, 97:2998-3006.
27. Endo M, Kawano T: Detection and classification of early squamous cell esophageal cancer. Dis Esophagus 1997, 10:155-158.
28. Ruol A, Merigliano S, Baldan N, et al.: Prevalence, management and outcome of early adenocarcinoma (pT1) of the esophagogastric junction. Comparison between early cancer in Barrett's esophagus (type I) and early cancer of the cardia (type II). Dis Esophagus 1997, 10:190-195.
29. May A, Gossner L, Pech O, et al.: Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002, 14:1085-1091.
30. Krishnadath KK, Wang KK, Taniguchi K, et al.: Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000, 119:624-630.
31. Wong DJ, Paulson TG, Prevo LJ, et al.: p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001, 61:8284-8289.
32. Wang KK, Kim JY: Photodynamic therapy in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003, 13:483-489.
33. Barr H: Barrett's esophagus: treatment with 5-aminolevulinic acid photodynamic therapy. Gastrointest Endosc Clin N Am 2000, 10:421-437.
34. Rice TW, Falk GW, Achkar E, Petras RE: Surgical management of high-grade dysplasia in Barrett's esophagus [see comments]. Am J Gastroenterol 1993, 88:1832-1836.
35. Finlayson EV, Goodney PP, Birkmeyer JD: Hospital volume and operative mortality in cancer surgery: a national study. Arch Surg 2003, 138:721-725; discussion 726.
36. Birkmeyer JD, Stukel TA, Siewers AE, et al.: Surgeon volume and operative mortality in the United States. N Engl J Med 2003, 349:2117-2117.
37. Luketich JD, Grondin SC, Pearson FG, et al.: Minimally invasive esophagectomy. Ann Thorac Surg 2000, 70:906-911; discussion 911-912.
38. Banki F, Mason RJ, DeMeester SR, et al.: Vagal-sparing esophagectomy: a more physiologic alternative. Ann Surg 2002, 236:324-335.